Bausch + Lomb Announces Second R&D "Teach-in" Webinar

About this update from Bausch + Lomb Corporation

Event will feature detailed overviews of two innovative contact lens technologies with potential to redefine the standard of care VAUGHAN, Ontario, May 06, 2026 --( BUSINESS WIRE )--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the second event in its R&D "Teach-in" webinar series that provides deeper insights on the company’s robust and differentiated product pipeline. On Monday, June 1, 2026, at 1:00 p.m. ET, Executive Vice President of Research & Development and Chief Medical Officer Yehia Hashad, MD, will be joined by members of his leadership team to discuss two promising contact lens assets currently under development: Chairman and CEO Brent Saunders and Executive Vice President and Chief Financial Officer Sam Eldessouky will also participate. Registration for the live webinar hosted by Citi as part of its Head, Shoulders, Knees, and Toes series can be accessed here . Following the event, a replay will be available on the Investor Relations page of the Bausch + Lomb website. About Bausch + Lomb Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook , Instagram , LinkedIn , X and YouTube . © 2026 Bausch + Lomb. View source version on businesswire.com: https://www.businesswire.com/news/home/20260506582450/en/ Contacts Media Contact: Chris Clark [email protected] (848) 360-1100 Investor Contact: George Gadkowski [email protected] (877) 354-3705 (toll free)

View stock analysis, news, and events for Bausch + Lomb Corporation